Correlation of systemic immune-inflammation and prognostic nutritional indices with pathological characteristics and prognosis in gastric cancer

Table 4 Univariate analysis of factors influencing 3-year prognosis in gastric cancer patients, n (%)

Indicator	Poor prognosis group (n = 37)	Good prognosis group (n = 70)	χ2 value	P value
Gender			0.888	0.346
Male (n = 70)	22 (59.46)	48 (68.57)
Female (n = 37)	15 (40.54)	22 (31.43)
Age (years)			1.324	0.250
< 60 (n = 63)	19 (51.35)	44 (62.86)
≥ 60 (n = 44)	18 (48.65)	26 (37.14)
Maximum tumor diameter (cm)			0.463	0.497
< 4 (n = 54)	17 (45.95)	37 (52.86)
≥ 4 (n = 53)	20 (54.05)	33 (47.14)
Differentiation degree			0.151	0.698
Moderate-to-high differentiation (n = 35)	13 (35.14)	22 (31.43)
Low differentiation (n = 72)	24 (64.86)	48 (68.57)
Tumor location			0.965	0.617
Cardia and fundic region (n = 19)	5 (13.51)	14 (20.00)
Gastric body (n = 22)	7 (18.92)	15 (21.43)
Pyloric region (n = 66)	25 (67.57)	41 (58.57)
Borrmann type			0.676	0.411
I-II (n = 35)	14 (37.84)	21 (30.00)
III-IV (n = 72)	23 (62.16)	49 (70.00)
Invasion depth			0.606	0.436
T1-T2 (n = 27)	11 (29.73)	16 (22.86)
T3-T4 (n = 80)	26 (70.27)	54 (77.14)
Metastases to lymph nodes			5.319	0.021
N0-N1 (n = 54)	13 (35.14)	41 (58.57)
N2-N3 (n = 53)	24 (64.86)	29 (41.43)
Distant metastasis			10.070	0.002
M0 (n = 68)	16 (43.24)	52 (74.29)
M1 (n = 39)	21 (56.76)	18 (25.71)
TNM staging			5.260	0.022
I-II (n = 51)	12 (32.43)	39 (55.71)
III-IV (n = 56)	25 (67.57)	31 (44.29)
CA199 (U/mL)			2.034	0.154
< 35 (n = 81)	25 (67.57)	56 (80.00)
≥ 35 (n = 26)	12 (32.43)	14 (20.00)
CEA (ng/mL)			3.660	0.056
< 5 (n = 86)	26 (70.27)	60 (85.71)
≥ 5 (n = 21)	11 (29.73)	10 (14.29)

TNM: Tumor-node-metastasis; CA199: Carbohydrate antigen 199; CEA: Carcinoembryonic antigen.